Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relugolix - Sumitomo Pharma America/Takeda

Next Previous
Drug Profile

Relugolix - Sumitomo Pharma America/Takeda

Alternative Names: MVT-601 - Sumitomo Pharma America/Takeda; ORGOVYX; Relumina; RVT 601; T-1331285; TAK-385

Latest Information Update: 17 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer ASKA Pharmaceutical; Sumitomo Pharma America; Takeda; Takeda Oncology
  • Class Analgesics; Antineoplastics; Fluorobenzenes; Ketones; Pyridazines; Pyrimidines; Small molecules; Thiophenes; Urea compounds
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Registered Endometriosis; Uterine leiomyoma
  • Phase II Pain
  • No development reported Solid tumours

Most Recent Events

  • 05 Jun 2025 Knight Therapeutics in-licenses Relugolix from Sumitomo Pharma America in Canada
  • 02 Jan 2025 Myovant completes the phase III REPLACE-CV trial for Prostate cancer (Late-stage disease, Metastatic disease) in the US (PO, Tablet) (NCT05605964)
  • 05 Nov 2024 Qilu Pharmaceutical plans a phase III trial in Uterine leiomyoma in China (In adults) (PO) in January 2025 (NCT06671548)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top